JOHNSON & JOHNSON (JNJ.DE) Stock Price, Forecast & Analysis
Europe • Frankfurt Stock Exchange • FRA:JNJ • US4781601046
JNJ.DE Key Statistics, Chart & Performance
The current stock price of JNJ.DE is 195.48 EUR. In the past month the price increased by 12.36%. In the past year, price increased by 30.46%.
JNJ.DE Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to JNJ.DE. When comparing the yearly performance of all stocks, JNJ.DE is one of the better performing stocks in the market, outperforming 87.35% of all stocks.
JNJ.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to JNJ.DE. Both the profitability and the financial health of JNJ.DE get a neutral evaluation. Nothing too spectacular is happening here.
JNJ.DE Financial Highlights
Over the last trailing twelve months JNJ.DE reported a non-GAAP Earnings per Share(EPS) of 9.12. The EPS increased by 8.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 27.26% | ||
| ROA | 13.03% | ||
| ROE | 31.69% | ||
| Debt/Equity | 0.55 |
JNJ.DE Forecast & Estimates
32 analysts have analysed JNJ.DE and the average price target is 182.77 EUR. This implies a price decrease of -6.5% is expected in the next year compared to the current price of 195.48.
For the next year, analysts expect an EPS growth of 7.03% and a revenue growth 6.76% for JNJ.DE
JNJ.DE Ownership
JNJ.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| SNW.DE | SANOFI | 11.47 | 194.96B | ||
| 1SAN.MI | SANOFI | 11.45 | 194.74B | ||
| SAN.PA | SANOFI | 11.47 | 195.06B | ||
| MRK.DE | MERCK KGAA | 14.56 | 54.00B | ||
| UNC.DE | UCB SA | 40.65 | 50.77B | ||
| UCB.BR | UCB SA | 40.87 | 51.04B | ||
| BAYN.DE | BAYER AG-REG | 8.45 | 44.34B | ||
| 1BAYN.MI | BAYER AG-REG | 8.4 | 44.05B | ||
| IPN.PA | IPSEN | 13.16 | 11.33B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 107.45 | 9.95B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 24.22 | 9.98B | ||
| 1JAZZ.MI | JAZZ PHARMACEUTICALS PLC | 19.91 | 8.34B |
Related stock screener links
About JNJ.DE
Company Profile
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. The company is headquartered in New Brunswick, New Jersey and currently employs 138,100 full-time employees. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
Company Info
JOHNSON & JOHNSON
One Johnson & Johnson Plaza
New Brunswick NEW JERSEY US
Employees: 138100
Phone: 17325242455
JOHNSON & JOHNSON / JNJ.DE FAQ
Can you describe the business of JOHNSON & JOHNSON?
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. The company is headquartered in New Brunswick, New Jersey and currently employs 138,100 full-time employees. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
What is the stock price of JOHNSON & JOHNSON today?
The current stock price of JNJ.DE is 195.48 EUR. The price increased by 0.75% in the last trading session.
Does JNJ stock pay dividends?
JOHNSON & JOHNSON (JNJ.DE) has a dividend yield of 2.29%. The yearly dividend amount is currently 4.12.
How is the ChartMill rating for JOHNSON & JOHNSON?
JNJ.DE has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the expected growth for JNJ stock?
The Revenue of JOHNSON & JOHNSON (JNJ.DE) is expected to grow by 6.76% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the number of employees for JOHNSON & JOHNSON?
JOHNSON & JOHNSON (JNJ.DE) currently has 138100 employees.
Who owns JOHNSON & JOHNSON?
You can find the ownership structure of JOHNSON & JOHNSON (JNJ.DE) on the Ownership tab.